Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

2. II.1.4.1

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as has taken the Authority), is inviting suitably qualified and experienced providers decision to respond to abandon this Competitive Process competitive provider selection process (effective from 30th June 2025) for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).As lifileucel, a result of cellular therapy for previously treated unresectable or metastatic melanoma (NICE ID 3863). NHS England remains committed to commissioning this procurement exercise an agreement will be established service, as this tumour infiltrating lymphocyte cell therapy progresses through the NICE TA process, in line with the successful bidder(s) for a period of three (3) years with the Commissioners having the option relevant procurement regulations and intends to extend progress this at the earliest suitable opportunity. Any future opportunities will be advertised in line with these the relevant procurement regulations, for up to an additional two (2) year(s) (maximum contract duration 5 years).The deadline for submissions example via the Find a Tender Service, and we will also notify all providers registered against the current process.This is 12.00pm (noon) on Tuesday 24th June 2025. a Provider Selection Regime (PSR) notice that this provider selection process has been abandoned and a contract has not been awarded. This process has been abandoned under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.